# Cranebio Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cranebio-co

- Industry: Medical Devices & Equipment
- Headquarters: Tokyo, Japan
- Website: www.crane-bio.com/
- Total disclosed funding: $4.3M
- Latest round: Series B (Jul 31, 2025)
- Investors on record: 6

## About

Founded in 2021 and based in Tokyo, Japan, Cranebio Co., Ltd. engages in the development and sales of a wearable medical device that detects hormones and diseases specific to women, test kits for infectious diseases such as COVID-19 and Influenza, and rapid test kits for water and food quality testing. In October 2023, Cranebio raised JPY 250 million in Series A funding from Akigin Capital Partners, Axil Capital Partners, and Nippon Venture Capital. As of 2023, the company is led by its president and CEO, Daisuke Yamamoto.

The company provides wearable testing kits to advance women’s health. These kits are designed for hormones and women-specific diseases, eliminating the need for invasive blood or urine samples. Cranebio also developed device-free genetic testing kits. These kits boast sensitivity comparable to PCR testing and can be used at home with saliva as the specimen.

In addition, the company offers rapid water and food sanitation test kits, providing instant results without the need for specialized equipment. These kits are applicable for infectious disease screening, water quality inspection, and food sanitation assessment, ensuring safety in various settings. The firm’s technology includes Dozyme, a technology harnessing DNA origami scaffolded enzymes that enables the development of highly sensitive medical testing kits for detecting viruses and bacteria, including COVID-19.

The organization plans to use the October 2023 funding to develop new products and strengthen its recruitment of researchers.

## Funding rounds

- Series B, Jul 31, 2025, $2.6M — Regional Economy Vitalization Corporation of Japan (REVIC), TOHOKU University Venture Partners, AGS Consulting, Akigin Capital Partners
- Series A, Oct 4, 2023, $1.7M — Nippon Venture Capital, Axil Capital, Akigin Capital Partners

## Investors

- Nippon Venture Capital (https://capitalatlas.ai/funds/nippon-venture-capital) — Series A
- Axil Capital (https://capitalatlas.ai/funds/axil-capital) — Series A
- Akigin Capital Partners (https://capitalatlas.ai/funds/akigin-capital-partners) — Series A, Series B
- Regional Economy Vitalization Corporation of Japan (REVIC) — Series B
- TOHOKU University Venture Partners (https://capitalatlas.ai/funds/tohoku-university-venture-partners) — Series B
- AGS Consulting (https://capitalatlas.ai/funds/ags-consulting) — Series B